PANKU-BREAST01

1. 00:00
   ESMO 2026 现场信号

   #ESMO26 | Izalontamab brengitecan nel carcinoma avanzato recidivante o metastatico HR+/HER- pre-trattato: l'efficacia di questo nuovo ADC è chiara, ma il vero interrogativo è un al

1. 20:45
   ESMO 2026 现场信号

   📈 Significant PFS improvements were shown with iza-bren vs chemotherapy in pretreated HR+/HER2– advanced breast cancer, according to new data from the phase 3 PANKU-Breast01 trial
2. 20:02
   中文产业新闻精选

   百利天恒伦康依隆妥单抗PANKU-Breast01三期结果发表于《柳叶刀》主刊，cORR 40.5%、mPFS 8.2个月

   百利天恒伦康依隆妥单抗PANKU-Breast01三期研究在HR+/HER2-晚期乳腺癌中显示，cORR为40.5%，mPFS为8.2个月。对照cORR为20.2%，mPFS较对照延长4.2个月，疾病进展或死亡风险降低59%（HR=0.41）；ILD发生率1.1%且均为1–2级。该新适应症上市申请已获受理，结果同期发表于《柳叶刀》主刊并在ESMO大会公布。

3. 05:36
   ESMO 2026 现场信号

   "High rate of hematologic toxicity, with ~50% G3+ anemia, neutropenia and thrombocytopenia, and most patients requiring dose reductions⚠️." @PTarantinoMD
4. 04:11
   ESMO 2026 现场信号

   🚨 #ESMO26 | PANKU-Breast01 🇨🇳
5. 02:02
   ESMO 2026 现场信号

   #ScienceLink #Madrid2026 #ESMO26 #PANKUBreast01 #IzalontamabBrengitecan
6. 00:40
   中文产业新闻

   伦康依隆妥单抗PANKU-Breast01 III期研究取得PFS主要终点阳性结果

   百利天恒的EGFR×HER3双抗ADC伦康依隆妥单抗在HR+HER2-晚期乳腺癌III期研究PANKU-Breast01中取得PFS主要终点阳性结果。该结果于2026年10月23日在ESMO大会Late-breaking Abstract环节公布，并同步发表于《柳叶刀》主刊全文。

1. 23:48
   ESMO 2026 现场信号

   #ESMO26 | Impressive results with a next-generation bispecific ADC!
2. 23:03
   ESMO 2026 现场信号

   #ESMO26 | PANKU-Breast01
3. 21:47
   ESMO 2026 现场信号

   PANKU-Breast01 | #ESMO26
4. 21:35
   ESMO 2026 现场信号

   PANKU-Breast01 at #ESMO26: izalontamab brengitecan, an EGFR×HER3 bispecific ADC, doubled PFS vs physician's-choice chemo in pretreated HR+/HER2- MBC (8.2 vs 4.0 mo, HR 0.41). A new
5. 21:07
   ESMO 2026 现场信号

   #ESMO2026
6. 21:02
   ESMO 2026 现场信号

   PANKU-Breast01 🇨🇳: dual EGFR and HER3 ADC Iza-Bren vs TPC in HR+/HER2- pre-treated MBC:
7. 21:02
   ESMO 2026 现场信号

   PANKU-Breast01 presented at #ESMO26
8. 20:58
   ESMO 2026 现场信号

   PANKU-Breast01
9. 20:58
   ESMO 2026 现场信号

   🇨🇳 PANKU-Breast01: the HER3-EGFR bispecific TOPO1 ADC Iza-Bren improved PFS vs chemo in HR+/HER2- MBC (OS immature). High rate of hematologic toxicity, with ~50% G3+ anemia, neutro
10. 20:58
    ESMO 2026 现场信号

    EGFRとHER3のbispecific抗体ADCのPANKU-Breast01試験。HR+MBCの化学療法既治療例が対象。有意にPFSを延長（HR 0.41）。ILDは1.1%。
11. 20:58
    ESMO 2026 现场信号

    #ESMO26 | PANKU-Breast01
12. 20:56
    ESMO 2026 现场信号

    PANKU-Breast01
13. 19:33
    ESMO 2026 现场信号

    Presenting at #ESMO2026—Izalontamab brengitecan for HR+/HER2– breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial https://spkl.io/60157kJtJ @myESMO
14. 13:13
    ESMO 2026 现场信号

    #ESMO26 | PANKU-Breast01
15. 07:56
    ESMO 2026 现场信号

    🚨 ESMO 2026 | PANKU-Breast01 (LBA50) #esmo26

1. 18:12
   ESMO 2026 现场信号

   🚨 #ESMO26 Breast Cancer: Top Ten by @OncoAlert 🎗️ The abstracts our faculty flagged as must-know from MADRID🇪🇸 👇 1️⃣ PANKU-Breast01 (LBA50): iza-bren in HR+/HER2− mBC 2️⃣ FOURLIG…

当前热度 83·可比范围峰值 144（10月24日 06:00）·近 24 小时可比范围变化 -34%·当前参与者 22

上图是参与者计数，下图是热度。趋势仅比较持续完整观测到的相同主体，范围可能小于当前热度统计。移动指针或点击图表查看每小时读数；键盘可用左右方向键切换。